Bruder-Nascimento Thiago, Kress Taylor C, Belin de Chantemele Eric J
Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA, USA.
Department of Pediatrics, Division of Endocrinology, University of Pittsburgh, Pittsburgh, PA, USA.
F1000Res. 2019 Oct 16;8. doi: 10.12688/f1000research.20150.1. eCollection 2019.
Lipodystrophy is a disease characterized by a partial or total absence of adipose tissue leading to severe metabolic derangements including marked insulin resistance, type 2 diabetes, hypertriglyceridemia, and steatohepatitis. Lipodystrophy is also a source of major cardiovascular disorders which, in addition to hepatic failure and infection, contribute to a significant reduction in life expectancy. Metreleptin, the synthetic analog of the adipocyte-derived hormone leptin and current therapy of choice for patients with lipodystrophy, successfully improves metabolic function. However, while leptin has been associated with hypertension, vascular diseases, and inflammation in the context of obesity, it remains unknown whether its daily administration could further impair cardiovascular function in patients with lipodystrophy. The goal of this short review is to describe the cardiovascular phenotype of patients with lipodystrophy, speculate on the etiology of the disorders, and discuss how the use of murine models of lipodystrophy could be beneficial to address the question of the contribution of leptin to lipodystrophy-associated cardiovascular disease.
脂肪营养不良是一种以部分或完全缺乏脂肪组织为特征的疾病，会导致严重的代谢紊乱，包括明显的胰岛素抵抗、2型糖尿病、高甘油三酯血症和脂肪性肝炎。脂肪营养不良也是主要心血管疾病的一个来源，除了肝衰竭和感染外，还会导致预期寿命显著缩短。米泊美生是脂肪细胞衍生激素瘦素的合成类似物，也是目前脂肪营养不良患者的首选治疗药物，它能成功改善代谢功能。然而，虽然在肥胖背景下，瘦素与高血压、血管疾病和炎症有关，但对于脂肪营养不良患者每日使用瘦素是否会进一步损害心血管功能仍不清楚。这篇简短综述的目的是描述脂肪营养不良患者的心血管表型，推测这些疾病的病因，并讨论如何利用脂肪营养不良的小鼠模型来解决瘦素对脂肪营养不良相关心血管疾病影响的问题。
